1839 Atty. Docket No.:

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Robinson, et al. on of: 09/484,629

January 18, 2000 Filed: **OBESITY GENE** Entitled:

Examiner:

Woitach, J.

Group Art Unit:

1632

**PATENT** 

## **CERTIFICATE OF MAILING UNDER 37 CFR 1.10**

I hereby certify that the paper (and any paper or fee referred to as being enclosed) is being deposited with the United States Postal Service using Express Mail to Addressee Service, under 37 C.F.R. Section 1.10, Express Mail Label No. EL728728929US on this date, May 2, 2001, postage prepaid, in an envelope addressed to Box: Patent Application, Commissioner for Patents, Washington, D.C. 20231.

Kathleen M. Williams Name of Person Mailing Paper Signature of Person Mailing Paper

**Box: SEQUENCE LISTING Commissioner for Patents** Washington, D.C. 20231

MAY 0 7 2001

## TRANSMITTAL LETTER

TECH CENTER 1600/2900

Enclosed for filing the above-identified patent application, please find the following documents:

- Amendment and Response to Notice to Comply with Requirements for Patent 1. Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures;
  - Copy of Notice to Comply; 2.
  - Paper copy of Sequence Listing; 3.
  - Computer readable copy of the Sequence Listing; 4.
  - Substitution of sheets containing new SEQ ID Nos.; 5.
  - Two month Extension of Time for Filing the Response to Notice to Comply With 6. Requirements for Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures;
  - Check in the amount of \$195.00 to cover fee for Extension of Time; and 7.
  - Return Post Card. 8.

The Commissioner for Patents is hereby authorized to charge any additional fees or credit any overpayment in the total fees to Deposit Account No. 16-0085, Reference 18396/1140. A duplicate of this transmittal letter is enclosed for this purpose.

Respectfully submitted, May 2, 2001 Name: Kathleen M. Williams Registration No.: 34,380 Palmer & Dodge LLP

One Beacon Street Boston, MA 02108 Tel: 617-573-0100

## NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING PHUCE EOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Northe is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

ing reason(s):
1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
7. Other: Applicants response was incomplete. The amendment did not contain new SEQ ID NOs for the sequences recited in the claims, nor a CRF diskette.
Applicant Must Provide:
An initial or <u>substitute</u> computer readable form (CRF) copy of the "Sequence Listing".
An initial or <u>substitute</u> paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).
For questions regarding compliance to these requirements, please contact:
For Rules Interpretation, call (703) 308-4216 For CRF Submission Help, call (703) 308-4212 PatentIn Software Program Support Technical Assistance
To Purchase PatentIn Software703-306-2600
DI EASE BETLIPN A COPY OF THIS NOTICE WITH YOUR REPLY

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY



Applicants Copy UNITED STATES DEPARTMENT **Patent and Trademark Office** COMMISSIONER OF PATENTS AND TRADEMARKS

Washington, D.C. 20231

ATTORNEY DOCKET NO. FIRST NAMED APPLICANT SERIAL NUMBER FILING DATE 018396/1140 Robinson et al. 09/484,629 01/18/2000

EXAMINER		
Joseph T. Woitach		
ART UNIT	PAPER NUMBER	
1632	16	

## Please find below a communication from the EXAMINER in charge of this application

Applicants' amendments filed April 5, 2001, papers 12-15, have been received and entered. Applicants election of Group II with traverse is noted.

The communication filed April 5, 2001, is not fully responsive to the Office communication mailed February 2, 2001, for the reason(s) set forth on the attached Notice To Comply With The Sequence Rules and below. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825) before the application can be examined under 35 U.S.C. §§ 131 and 132.

If a complete reply has not been submitted by the time the period set in the Office communication mailed February 2, 2001 has expired, this application will become abandoned under 37 CFR 1.821(g) unless applicant corrects the deficiency and obtains an extension of time under 37 CFR 1.136(a).

As noted in the previous office action, the claims contain polynucleotide and polypeptide sequences which do not have SEQ ID NOs, and a new sequence listing containing these sequences and a new CRF diskette must be submitted.

Any inquiry concerning this communication should be directed to Examiner Joseph T. Woitach Art Unit 1632, whose telephone number is (703)305-3732.

Any inquiry of a general nature or relating to the status of this application should be directed to Kay Pinkney whose telephone number is (703)305-3553.

> SCOTT D. PRIEBE, PH.D. PRIMARY EXAMINER